In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) reported that Armistice Capital has picked up 1,144,000 of common stock as of 2017-06-01.
The acquisition brings the aggregate amount owned by Armistice Capital to a total of 1,144,000 representing less than 5.12% stake in the company.
For those not familiar with the company, Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
A glance at Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s key stats reveals a current market capitalization of 448.71 Million based on 25.25 Million shares outstanding and a price at last close of $16.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-16, Ericson picked up 8,240 at a purchase price of $16.81. This brings their total holding to 4,031,804 as of the date of the filing.
On the sell side, the most recent transaction saw Went unload 2,807 shares at a sale price of $17.03. This brings their total holding to 166,526.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.